Syndax Pharmaceuticals, Inc. (SNDX)

Market Cap	1.44B
Revenue (ttm)	111.30M
Net Income (ttm)	-311.58M
Shares Out	86.91M
EPS (ttm)	-3.60
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,325,550
Open	16.58
Previous Close	16.66
Day's Range	16.42 - 17.27
52-Week Range	8.58 - 18.00
Beta	0.52
Analysts	Strong Buy
Price Target	37.09 (+123.17%)
Earnings Date	Nov 3, 2025

About SNDX

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combinati...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 3, 2016
• Employees: 270
• Stock Exchange: NASDAQ
• Ticker Symbol: SNDX
• Website: https://syndax.com

Analyst Summary

According to 11 analysts, the average rating for SNDX stock is "Strong Buy." The 12-month stock price target is $37.09, which is an increase of 123.17% from the latest price.

Price Target

$37.09

(123.17% upside)

Analyst Consensus: Strong Buy